The Frontline of Alzheimer's Care: Addressing Real Questions from Clinicians in the New Dawn of Disease-Modifying Therapy

Due to the unique educational design of this course, the content must be viewed and completed on the ReachMD platform.

Program Description

Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.    

Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise

Target Audience

This activity is intended for neurologists, psychiatrists, geriatricians, general practice and internal medicine physicians, and other advanced practice professionals, registered nurses, and pharmacists involved in the diagnosis and management of Alzheimer’s disease.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Discuss novel challenges and practice considerations among medical professionals who plan to use amyloid targeting therapy (ATT) and utilize expert solutions to develop optimized corresponding management strategies
  • Contrast the roles and accessibility of cognitive (e.g., MoCA), radiological (e.g., PET), and laboratory (e.g., CSF, serum) assessments in determining and staging AD pathology to more readily identify individuals eligible for new and emerging disease-modifying therapies (DMTs)
  • Evaluate and compare the efficacy, safety, and administration/monitoring protocols of approved and emerging ATTs to better guide how and for whom these approaches may be utilized in clinical practice
  • Appraise the risk factors, symptoms, and / management strategies surrounding amyloid-related imaging abnormalities (ARIA) to prepare for timely recognition of and effective response to these events
Course summary
Course opens: 
01/31/2024
Course expires: 
01/31/2025
Cost:
$0.00
Rating: 
0
  Richard S. Isaacson, MD
  Director, Center for Brain Health,
  Schmidt College of Medicine
  Florida Atlantic University
  Boca Raton, FL
 
 
 
 
 
 
  Pierre N. Tariot, MD
  Director, Banner Alzheimer's Institute
  Research Professor of Psychiatry,
  University of Arizona
  Phoenix, AZ
 
 
 
 
 
  Gayatri Devi, MD, MS, FAAN, FACP
  Clinical Professor of Neurology and Psychiatry
  Zucker School of Medicine at Hofstra/Northwell
  Director, Park Avenue Neurology
  New York, NY

    This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.

       

    Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Designation Statement

    PHYSICIAN CREDIT
    Medical Education Resources designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
    A Certificate of Participation will be given upon completion of the activity enabling participants to register their credit with the appropriate licensing boards or associations.

    Disclosure of Relevant Financial Relationships

    Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in an accredited continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality accredited continuing education activities that promote improvements or quality in health care and not the business interest of an ineligible company.

    Staff Disclosures

    Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose.

    Faculty Disclosures

    The program faculty reported the following relevant financial relationships that they have with commercial interests:

    Dr. Isaacson:

    • Consulting Fees: Acadia, Novo Nordisk

    Dr. Tariot:

    • Consulting Fees: Abbvie, Acadia, AC Immune, Athira, Corium, Eisai, Genentech, Immunobrain, Lundbeck, Merck, Miller Medical Communications, Novo Nordisk, Otsuka & Astex, T3D Therapeutics

    • Grants/Research Support: Abbvie, Biogen, Cortexyme, Eli Lilly, Genentech, Merck, National Institute of Aging (RF1 AG041705, 1UF1AG046150, R01 AG031581, R01 AG055444, P30 AG19610), NIA, Novartis, Roche

    Dr. Devi has reported no financial relationships

    Disclosure of Unlabeled Use/Disclaimer

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer

    The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Lilly. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

    Commercial Support

    This continuing education activity is supported by an educational grant from Lilly.

    Method of Participation

    There are no fees for participating in and receiving credit for this activity. During the period December 20, 2023 through December 20, 2024, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

    A statement of credit will be issued only upon receipt of a completed activity evaluation form.

    Media

    Internet

    Price

    Cost:
    $0.00
    Please login or register to take this course.
    Due to the unique educational design of this course, the content must be viewed and completed on the ReachMD platform.